SCHEMBL4479748

SCHEMBL4479748

Nc1ccc2cnn(Cc3ccccc3)c2c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.66
BRD4 O60885 2/20 0.51
TSHR P16473 1/20 0.50
KDM4C Q9H3R0 1/20 0.47
CNR1 P21554 1/20 0.46
ACHE P22303 1/20 0.46
CNR2 P34972 1/20 0.46
ERBB2 P04626 2/20 0.46
ALDH1A1 P00352 2/20 0.43
PRMT5 O14744 1/20 0.43
KMO O15229 2/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MPO P05164 1/20 0.41
EGFR P00533 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29992643 0.88 RECQL (0.66) RECQLBRD4TSHRKDM4CCNR1
SCHEMBL870390 0.88 RECQL (0.66) RECQLBRD4TSHRKDM4CCNR1
SCHEMBL1015246 0.84 RECQL (0.47) RECQLERBB2EGFRHTR2AHTR2C
SCHEMBL30694932 0.81 RECQL (0.66) RECQLBRD4TSHRKDM4CERBB2
SCHEMBL18558982 0.81 RECQL (0.66) RECQLBRD4TSHRKDM4CERBB2
SCHEMBL12930779 0.81 RECQL (0.66) RECQLBRD4TSHRKDM4CERBB2
SCHEMBL4215903 0.81 RECQL (0.66) RECQLBRD4TSHRKDM4CALDH1A1
SCHEMBL2543455 0.81 RECQL (0.66) RECQLBRD4TSHRKDM4CERBB2
SCHEMBL4831197 0.81 RECQL (0.75) RECQLTSHRERBB2ALDH1A1KMO
SCHEMBL5863967 0.81 TDP1 (0.56) RECQLBRD4TSHRCNR1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3676255-B1 THERAPEUTIC INDAZOLES RUTGERS THE STATE UNIV UNIV OF NEW JERSEY (US) 2025-04-16 EP disclosed
US-12060330-B2 Therapeutic indazoles RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-08-13 US disclosed
CN-111479805-B Therapeutic indazoles 罗格斯新泽西州立大学 2024-08-13 CN disclosed
US-20220144781-A1 THERAPEUTIC INDAZOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-05-12 US disclosed
US-11186549-B2 Therapeutic indazoles RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2021-11-30 US disclosed
CN-111479805-A Therapeutic indazoles 罗格斯新泽西州立大学 2020-07-31 CN disclosed
EP-3676255-A1 THERAPEUTIC INDAZOLES Rutgers, The State University University Of New Jersey (US) 2020-07-08 EP disclosed
US-20200199076-A1 THERAPEUTIC INDAZOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-06-25 US disclosed
WO-2019046467-A1 THERAPEUTIC INDAZOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-03-07 WO disclosed
EP-2817310-B1 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2018-03-21 EP disclosed
US-5440035-A Leukotriene antagonists; antiallergens, antiinflammatory agents ZENECA INC. (GB) 1995-08-08 US disclosed
US-5391758-A Leukotriene antagonists ZENECA, INC. (US) 1995-02-21 US disclosed
US-5338734-A Leukotriene antagonist properties; antiinflammatory agents ZENECA INC. (US) 1994-08-16 US disclosed
US-5179112-A Leukotriene antagonist as antiallergens and antiinflammatory agents ICI AMERICAS INC. (US) 1993-01-12 US disclosed
CN-1017425-B Process for preparing heterocyclic amide derivatives ICI AMERICA INC (US) 1992-07-15 CN disclosed
EP-0199543-B1 HETEROCYCLIC AMIDE DERIVATIVES ICI AMERICAS INC. (US) 1991-12-04 EP disclosed
US-5030643-A Antiallergens, antiinflammatory agents ICI AMERICAS INC. (US) 1991-07-09 US disclosed
US-4859692-A Heterocyclic amide derivatives and pharmaceutical use ICI AMERICAS INC. (US) 1989-08-22 US disclosed
CN-86103278-A The method for preparing heterocyclic amide derivative 1986-12-17 CN disclosed
EP-0199543-A2 Heterocyclic amide derivatives ICI AMERICAS INC. (US) 1986-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060330-B2 Therapeutic indazoles RIF1, QTRT1, NQO2 RECQL 377/4885BRD4 217/4885TSHR 66/4885
US-20220144781-A1 THERAPEUTIC INDAZOLES RIF1, QTRT1, NQO2 RECQL 377/4885BRD4 217/4885TSHR 66/4885
US-20200199076-A1 THERAPEUTIC INDAZOLES RIF1, NQO2, QTRT1 RECQL 341/4885BRD4 262/4885TSHR 105/4885
US-11186549-B2 Therapeutic indazoles RIF1, NQO2, QTRT1 RECQL 341/4885BRD4 262/4885TSHR 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.